PTC Therapeutics Reports Third-Quarter Revenue of $357.8 Million
Story updates
08:05:01 PM UTC
SquawkNews
Strong Q3 2026 performance with total revenue of $358 million, including $276 million of product r
Related stories
Varun Beverages Q3 Net Profit Rises 13.5% to ₹830.6 Crore
The company reported a 13.5% year-on-year increase in consolidated net profit for the July-September 2026 quarter. Its shares fell 4.39% to an intraday low of ₹396.5.
H impact | EQUITY | Oct 31, 2026, 04:13 AM UTC
Intel Shares Fall 29%, Their Worst One-Day Drop Since the 1970s
Intel shares fell 29% Friday after the chipmaker warned that a factory shutdown in Israel and a weak PC market would hit quarterly earnings. The decline erased about $12 billion fr
H impact | EQUITY | Oct 31, 2026, 03:51 AM UTC
BMV Gains 8.67% in October as Wall Street Closes Lower
The BMV rose 8.67% for the month, while Wall Street ended October lower.
M impact | EQUITY | Oct 31, 2026, 03:41 AM UTC
Intel Shares Plunge 30% on Production Problems and Weaker PC Demand
Intel shares fell 30% in Wall Street trading amid production problems and declining PC demand.
H impact | EQUITY | Oct 31, 2026, 03:23 AM UTC
Abound Declares H2Si Power in Default of License Agreement
Abound Energy says it has declared H2Si Power, Amerada R&D and Robert McKenzie in material default of the H2Si Technology Commercialization license agreement.
M impact | EQUITY | Oct 31, 2026, 01:54 AM UTC
Freedom Broker Raises Mondelez to Buy From Hold
Freedom Broker raised its rating on Mondelez from Hold to Buy.
H impact | EQUITY | Oct 31, 2026, 01:48 AM UTC